Rejected from NEJM? The 7 Best Journals to Submit Next

NEJM's editorial criteria are some of the most clearly defined among top medical journals, which actually helps you diagnose the rejection and plan your next move.### What NEJM editors want

NEJM editors evaluate manuscripts against three criteria simultaneously:

• Practice-changing potential: This is the single most important factor. NEJM wants papers whose results, if confirmed, would change what doctors do in the clinic tomorrow. Not next year. Not after three more confirmatory trials. Tomorrow. A positive Phase III trial comparing a new treatment to standard of care hits this bar. A subgroup analysis of an existing trial usually doesn't.
• Clinical trial rigor: NEJM sets the standard for trial methodology. The journal expects proper randomization, adequate power, pre-specified primary endpoints, intention-to-treat analysis, and independent data monitoring. Methodological shortcuts that other journals might overlook will get you desk-rejected at NEJM.
• Relevance to practicing physicians: NEJM's primary readership is practicing clinicians, not bench scientists. Papers need to speak to clinical decision-making. A beautiful mechanistic study that doesn't connect to a clinical question won't get past the desk, no matter how elegant the science.

NEJM's three-stage filter

• Stage 1: Desk review (~80% rejected): An editor reads your abstract and cover letter. If the study doesn't appear practice-changing for NEJM's readership, it's rejected within one to two weeks. This is fast, efficient, and tells you nothing about your paper's quality.
• Stage 2: External peer review (~50% rejected): If you clear the desk, your odds improve dramatically, but roughly half of peer-reviewed papers are still rejected. Reviewers at this stage are evaluating methodology, completeness, and whether the conclusions follow from the data.
• Stage 3: Revision and acceptance (~70-80% accepted): If NEJM asks for revisions, you're in strong shape. Most revision requests lead to acceptance. Don't fumble this stage by submitting a sloppy revision.

Common NEJM rejection reasons

• "Insufficient clinical impact for NEJM's readership.": This is the most common desk rejection language. It means your paper is probably good, but the finding doesn't change clinical practice at the scale NEJM requires. A well-designed trial in a niche surgical population, for example, may be excellent work but wrong for NEJM.
• "We receive many more papers than we can publish.": The polite version of "your paper isn't competitive for our limited slots." This could mean the science is fine but they have six other papers on the same topic this quarter.
• "Study design limitations.": Less common at the desk, but NEJM will flag underpowered studies, observational designs when a trial was feasible, or post-hoc analyses immediately.

Before choosing your next journal, a NEJM manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

• Large clinical trial rejected at the desk?: Go straight to The Lancet or JAMA. Don't waste time on lower-tier journals. A trial that NEJM considered but rejected is competitive anywhere.
• Specialty-focused trial rejected?: Try JAMA Internal Medicine, JAMA Oncology (for cancer trials), or a Lancet specialty journal. These journals have IFs above 20 and publish the trials that define specialty practice.
• Observational study or epidemiology rejected?: The BMJ and PLOS Medicine are more receptive to observational designs than NEJM. The BMJ in particular has championed well-conducted observational research.
• Rejected after peer review?: You have expert feedback. Fix what you can, then submit to The Lancet, JAMA, or The BMJ with a cover letter that explains what you've revised. Some of these journals will accept transferred reviewer reports.

• Reframe the clinical significance: NEJM wants practice-changing evidence. The Lancet wants global impact. JAMA wants clinical relevance. The BMJ wants evidence-based policy. Same data, different emphasis.
• Adjust the introduction: Don't recycle your NEJM introduction word-for-word. Each journal's readership has different priorities, and the first two paragraphs should signal that your paper belongs in their specific journal.
• Update your cover letter completely: A cover letter that says "we previously submitted this work to another leading medical journal" without specifics signals that you're carpet-bombing. Instead, explain concretely why this journal is the right home for your specific findings.
• Address any methodological gaps: If NEJM reviewers flagged statistical issues, missing sensitivity analyses, or incomplete reporting, fix these before submitting anywhere. Those same issues will surface at the next journal.

The Lancet is NEJM's closest competitor. Both publish landmark clinical trials, but The Lancet has a different editorial lens. Where NEJM asks "does this change clinical practice?", The Lancet asks "does this change clinical practice globally?" That distinction matters. If NEJM rejected your paper because the finding was "too focused on a specific population," The Lancet might see global health implications NEJM didn't prioritize. Conversely, if NEJM rejected a US-specific trial, The Lancet may agree that the geographic scope is limited.

Best for: Clinical trials with global health implications. Large epidemiological studies. Health policy research with clinical outcomes data.

JAMA is the other major US general medical journal. Where NEJM demands practice-changing evidence, JAMA has a slightly broader aperture. JAMA publishes strong clinical research that informs medical practice even if it doesn't immediately change it. JAMA's network of specialty journals is a major advantage. If JAMA's editors think your paper fits better in a specialty venue, they may transfer it to JAMA Internal Medicine (IF ~39), JAMA Oncology (IF ~28), JAMA Cardiology (IF ~14), JAMA Neurology (IF ~20), or JAMA Surgery (IF ~15). These transfers preserve your editorial history and streamline review.

Best for: Clinical research with clear relevance to US medical practice. Well-designed studies that inform practice without necessarily changing it overnight.

The BMJ is the strongest option for papers that sit between clinical medicine and public health. The journal publishes clinical trials, systematic reviews, and epidemiological studies with a particular focus on evidence that informs guidelines and policy. The BMJ's editorial process is more transparent than NEJM's. Reviewers' identities are disclosed, and the journal publishes reviewer reports alongside accepted papers. This transparency tends to produce more constructive and balanced reviews.

Best for: Systematic reviews, meta-analyses, health services research, and observational studies. Papers with implications for clinical guidelines.

JAMA Internal Medicine is the top specialty journal for internal medicine and general clinical medicine. It publishes shorter-format research letters, original investigations, and clinical reviews with a focus on practical clinical questions. The journal has carved a niche for studies that challenge conventional wisdom or reveal unexpected findings in everyday medical practice. If your paper has a "doctors should rethink this common practice" angle, JAMA Internal Medicine rewards that.

Best for: Internal medicine research, clinical practice studies, health services research, and papers that challenge established practice patterns.

Annals is the official journal of the American College of Physicians and publishes the ACP clinical practice guidelines. That gives it direct influence on how internal medicine is practiced in the US and increasingly worldwide. The journal values methodological rigor and has a strong systematic review tradition. If your paper contributes evidence that could inform a practice guideline, Annals is where it will have the most direct impact on clinical practice.

Best for: Internal medicine clinical trials, systematic reviews that inform guidelines, and papers on screening, prevention, and primary care.

For papers at the translational boundary, where clinical outcomes meet biological mechanism, Nature Medicine offers something the general medical journals don't. NEJM wants to know what works in patients. Nature Medicine wants to know why it works and what that reveals about disease biology. If NEJM rejected your paper because it was "too mechanistic" or "too translational," Nature Medicine is the right target. The journal's IF (~82) is actually comparable to NEJM's in some years, so this isn't a step down. It's a different audience.

Best for: Translational research, biomarker discovery, disease mechanism studies with clinical data, and precision medicine papers.

PLOS Medicine is the top open-access general medical journal. It publishes clinical research, systematic reviews, and global health studies with a commitment to transparent methodology and open data. The APC ($4,600) is a consideration, but PLOS offers waivers for authors from qualifying countries. If your paper has a global health dimension and you want broad open-access reach, PLOS Medicine provides that without the prestige gatekeeping of the subscription journals.

Best for: Global health research, systematic reviews, and clinical studies where open-access reach matters for the target audience (e.g., clinicians in resource-limited settings).

In our pre-submission review work with manuscripts targeting the New England Journal of Medicine, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Practice-change threshold not met. NEJM's editorial criterion is as specific as any in medicine: does this finding, if confirmed, change what a practicing clinician does for patients tomorrow? Not eventually, not in principle, but in the clinic. We see this failure as the dominant pattern in NEJM desk rejections we review: well-designed trials and cohort analyses where the finding is important within the specialty but does not reach the scale of clinical impact that NEJM requires. In our review of NEJM submissions, we find that editors consistently return papers where the clinical implication is real but incremental, even when the methodology is exemplary.

Observational design when a randomized trial was feasible. NEJM holds observational research to a higher bar than almost any other clinical journal because it primarily publishes randomized trial evidence that changes practice. We see this failure regularly in manuscripts we review: prospective cohort studies, registry analyses, and population data papers addressing clinical questions where a randomized trial was clearly feasible, or where strong trial evidence already exists and the observational findings are interpreted as causal without addressing this.

Insufficient generalizability of the clinical population studied. NEJM's readership spans all of clinical medicine, and editors require that findings matter to practicing internists, surgeons, and specialists broadly. We see this pattern in NEJM submissions we review present rigorous trials in narrow surgical subspecialties, rare hematological conditions, or highly selected patient populations where the finding is clearly meaningful to specialists but does not reach the generalizability NEJM requires to justify its flagship placement.

Reporting or methodological gaps visible at the desk. NEJM checks CONSORT compliance, pre-registration, and statistical rigor at the desk stage. Papers with post-hoc primary endpoints, underpowered efficacy analyses, or missing intention-to-treat data generate desk returns before reaching peer review. We see this pattern in clinical trial submissions we review for NEJM: otherwise strong trials where a methodological gap that NEJM considers foundational has not been addressed.

SciRev community data for NEJM confirms desk rejections typically arrive within 1-2 days, consistent with the rapid triage NEJM maintains as one of the highest-volume flagship medical journals.

• How to choose a journal for your paper
• Signs your paper is not ready to submit
• What pre-submission peer review includes

Before you resubmit, run your manuscript through a manuscript scope and readiness check to check fit, structure, and editorial risk before the next submission.